Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart

Yochai Birnbaum, Yumei Ye, Yu Lin, Sheldon Y. Freeberg, Ming He Huang, Jose R. Perez-Polo, Barry F. Uretsky

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Aspirin (ASA) inhibits cycloxygenase-1 and modifies cycloxygenase-2 (COX2) by acetylation at Ser530, leading to a shift from production of PGH2, the precursor of prostaglandin, to 15-R-HETE which is converted by 5-lipoxygenase to 15-epi-lipoxin A4 (15-epi-LXA4), a potent anti-inflammatory mediator. Both atorvastatin (ATV) and pioglitazone (PIO) increase COX2 expression. ATV activates COX2 by S-nitrosylation at Cys526 to produce 15-epi-LXA4 and 6-keto-PGF (the stable metabolite of PGI2). We assessed the effect of ASA on the myocardial production of 15-epi-LXA4 and PGI2 after induction by lipopolysaccharide (LPS) or PIO + ATV. Sprague-Dawley rats were pretreated with: control; ASA 10 mg/kg; ASA 50 mg/kg; LPS alone; LPS + ASA 10 mg/kg; LPS + ASA 50 mg/kg; LPS + ASA 200 mg/kg; PIO (10 mg/kg/d) + ATV (10 mg/kg/d); PIO + ATV + ASA 10 mg/kg; PIO + ATV + ASA 50 mg/kg; PIO + ATV + ASA 50 mg/kg + 1400 W, a specific iNOS inhibitor; or PIO + ATV + 1400 W. ASA alone had no effect on myocardial 15-epi-LXA4. LPS increased 15-epi-LXA4 and 6-keto-PGF levels. ASA (50 mg/kg and 200 mg/kg, but not 10 mg/kg) augmented the LPS effect on 15-epi-LXA4 but attenuated the effect on 6-keto-PGF. PIO + ATV increased 15-epi-LXA4 and 6-keto-PGF levels. ASA and 1400 W attenuated the effects of PIO + ATV on 15-epi-LXA4 and 6-keto-PGF. However, when both ASA and 1400 W were administered with PIO + ATV, there was a marked increase in 15-epi-LXA4, whereas the production of 6-keto-PGF was attenuated. In conclusion, COX2 acetylation by ASA shifts enzyme from producing 6-keto-PGF to 15-epi-LXA4. In contrast, S-nitrosylation by PIO + ASA augments the production of both 15-epi-LXA4 and 6-keto-PGF. However, when COX2 is both acetylated and S-nitrosylated, it is inactivated. We suggest potential adverse interactions among statins, thiazolidinediones, and high-dose ASA.

Original languageEnglish (US)
Pages (from-to)89-98
Number of pages10
JournalProstaglandins and Other Lipid Mediators
Volume83
Issue number1-2
DOIs
StatePublished - Feb 2007

Fingerprint

pioglitazone
Aspirin
Lipopolysaccharides
Rats
Acetylation
Epoprostenol
lipoxin A4
Atorvastatin Calcium
Prostaglandin H2
Hydroxyeicosatetraenoic Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Thiazolidinediones
Arachidonate 5-Lipoxygenase

Keywords

  • 15-Epi-lipoxin A
  • Aspirin
  • Atorvastatin
  • Cycloxygenase
  • Inflammation
  • Pioglitazone
  • Prostaglandins
  • S-Nitrosylation

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. / Birnbaum, Yochai; Ye, Yumei; Lin, Yu; Freeberg, Sheldon Y.; Huang, Ming He; Perez-Polo, Jose R.; Uretsky, Barry F.

In: Prostaglandins and Other Lipid Mediators, Vol. 83, No. 1-2, 02.2007, p. 89-98.

Research output: Contribution to journalArticle

Birnbaum, Yochai ; Ye, Yumei ; Lin, Yu ; Freeberg, Sheldon Y. ; Huang, Ming He ; Perez-Polo, Jose R. ; Uretsky, Barry F. / Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. In: Prostaglandins and Other Lipid Mediators. 2007 ; Vol. 83, No. 1-2. pp. 89-98.
@article{895551af2f964617aee181da05949df7,
title = "Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart",
abstract = "Aspirin (ASA) inhibits cycloxygenase-1 and modifies cycloxygenase-2 (COX2) by acetylation at Ser530, leading to a shift from production of PGH2, the precursor of prostaglandin, to 15-R-HETE which is converted by 5-lipoxygenase to 15-epi-lipoxin A4 (15-epi-LXA4), a potent anti-inflammatory mediator. Both atorvastatin (ATV) and pioglitazone (PIO) increase COX2 expression. ATV activates COX2 by S-nitrosylation at Cys526 to produce 15-epi-LXA4 and 6-keto-PGF1α (the stable metabolite of PGI2). We assessed the effect of ASA on the myocardial production of 15-epi-LXA4 and PGI2 after induction by lipopolysaccharide (LPS) or PIO + ATV. Sprague-Dawley rats were pretreated with: control; ASA 10 mg/kg; ASA 50 mg/kg; LPS alone; LPS + ASA 10 mg/kg; LPS + ASA 50 mg/kg; LPS + ASA 200 mg/kg; PIO (10 mg/kg/d) + ATV (10 mg/kg/d); PIO + ATV + ASA 10 mg/kg; PIO + ATV + ASA 50 mg/kg; PIO + ATV + ASA 50 mg/kg + 1400 W, a specific iNOS inhibitor; or PIO + ATV + 1400 W. ASA alone had no effect on myocardial 15-epi-LXA4. LPS increased 15-epi-LXA4 and 6-keto-PGF1α levels. ASA (50 mg/kg and 200 mg/kg, but not 10 mg/kg) augmented the LPS effect on 15-epi-LXA4 but attenuated the effect on 6-keto-PGF1α. PIO + ATV increased 15-epi-LXA4 and 6-keto-PGF1α levels. ASA and 1400 W attenuated the effects of PIO + ATV on 15-epi-LXA4 and 6-keto-PGF1α. However, when both ASA and 1400 W were administered with PIO + ATV, there was a marked increase in 15-epi-LXA4, whereas the production of 6-keto-PGF1α was attenuated. In conclusion, COX2 acetylation by ASA shifts enzyme from producing 6-keto-PGF1α to 15-epi-LXA4. In contrast, S-nitrosylation by PIO + ASA augments the production of both 15-epi-LXA4 and 6-keto-PGF1α. However, when COX2 is both acetylated and S-nitrosylated, it is inactivated. We suggest potential adverse interactions among statins, thiazolidinediones, and high-dose ASA.",
keywords = "15-Epi-lipoxin A, Aspirin, Atorvastatin, Cycloxygenase, Inflammation, Pioglitazone, Prostaglandins, S-Nitrosylation",
author = "Yochai Birnbaum and Yumei Ye and Yu Lin and Freeberg, {Sheldon Y.} and Huang, {Ming He} and Perez-Polo, {Jose R.} and Uretsky, {Barry F.}",
year = "2007",
month = "2",
doi = "10.1016/j.prostaglandins.2006.10.003",
language = "English (US)",
volume = "83",
pages = "89--98",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart

AU - Birnbaum, Yochai

AU - Ye, Yumei

AU - Lin, Yu

AU - Freeberg, Sheldon Y.

AU - Huang, Ming He

AU - Perez-Polo, Jose R.

AU - Uretsky, Barry F.

PY - 2007/2

Y1 - 2007/2

N2 - Aspirin (ASA) inhibits cycloxygenase-1 and modifies cycloxygenase-2 (COX2) by acetylation at Ser530, leading to a shift from production of PGH2, the precursor of prostaglandin, to 15-R-HETE which is converted by 5-lipoxygenase to 15-epi-lipoxin A4 (15-epi-LXA4), a potent anti-inflammatory mediator. Both atorvastatin (ATV) and pioglitazone (PIO) increase COX2 expression. ATV activates COX2 by S-nitrosylation at Cys526 to produce 15-epi-LXA4 and 6-keto-PGF1α (the stable metabolite of PGI2). We assessed the effect of ASA on the myocardial production of 15-epi-LXA4 and PGI2 after induction by lipopolysaccharide (LPS) or PIO + ATV. Sprague-Dawley rats were pretreated with: control; ASA 10 mg/kg; ASA 50 mg/kg; LPS alone; LPS + ASA 10 mg/kg; LPS + ASA 50 mg/kg; LPS + ASA 200 mg/kg; PIO (10 mg/kg/d) + ATV (10 mg/kg/d); PIO + ATV + ASA 10 mg/kg; PIO + ATV + ASA 50 mg/kg; PIO + ATV + ASA 50 mg/kg + 1400 W, a specific iNOS inhibitor; or PIO + ATV + 1400 W. ASA alone had no effect on myocardial 15-epi-LXA4. LPS increased 15-epi-LXA4 and 6-keto-PGF1α levels. ASA (50 mg/kg and 200 mg/kg, but not 10 mg/kg) augmented the LPS effect on 15-epi-LXA4 but attenuated the effect on 6-keto-PGF1α. PIO + ATV increased 15-epi-LXA4 and 6-keto-PGF1α levels. ASA and 1400 W attenuated the effects of PIO + ATV on 15-epi-LXA4 and 6-keto-PGF1α. However, when both ASA and 1400 W were administered with PIO + ATV, there was a marked increase in 15-epi-LXA4, whereas the production of 6-keto-PGF1α was attenuated. In conclusion, COX2 acetylation by ASA shifts enzyme from producing 6-keto-PGF1α to 15-epi-LXA4. In contrast, S-nitrosylation by PIO + ASA augments the production of both 15-epi-LXA4 and 6-keto-PGF1α. However, when COX2 is both acetylated and S-nitrosylated, it is inactivated. We suggest potential adverse interactions among statins, thiazolidinediones, and high-dose ASA.

AB - Aspirin (ASA) inhibits cycloxygenase-1 and modifies cycloxygenase-2 (COX2) by acetylation at Ser530, leading to a shift from production of PGH2, the precursor of prostaglandin, to 15-R-HETE which is converted by 5-lipoxygenase to 15-epi-lipoxin A4 (15-epi-LXA4), a potent anti-inflammatory mediator. Both atorvastatin (ATV) and pioglitazone (PIO) increase COX2 expression. ATV activates COX2 by S-nitrosylation at Cys526 to produce 15-epi-LXA4 and 6-keto-PGF1α (the stable metabolite of PGI2). We assessed the effect of ASA on the myocardial production of 15-epi-LXA4 and PGI2 after induction by lipopolysaccharide (LPS) or PIO + ATV. Sprague-Dawley rats were pretreated with: control; ASA 10 mg/kg; ASA 50 mg/kg; LPS alone; LPS + ASA 10 mg/kg; LPS + ASA 50 mg/kg; LPS + ASA 200 mg/kg; PIO (10 mg/kg/d) + ATV (10 mg/kg/d); PIO + ATV + ASA 10 mg/kg; PIO + ATV + ASA 50 mg/kg; PIO + ATV + ASA 50 mg/kg + 1400 W, a specific iNOS inhibitor; or PIO + ATV + 1400 W. ASA alone had no effect on myocardial 15-epi-LXA4. LPS increased 15-epi-LXA4 and 6-keto-PGF1α levels. ASA (50 mg/kg and 200 mg/kg, but not 10 mg/kg) augmented the LPS effect on 15-epi-LXA4 but attenuated the effect on 6-keto-PGF1α. PIO + ATV increased 15-epi-LXA4 and 6-keto-PGF1α levels. ASA and 1400 W attenuated the effects of PIO + ATV on 15-epi-LXA4 and 6-keto-PGF1α. However, when both ASA and 1400 W were administered with PIO + ATV, there was a marked increase in 15-epi-LXA4, whereas the production of 6-keto-PGF1α was attenuated. In conclusion, COX2 acetylation by ASA shifts enzyme from producing 6-keto-PGF1α to 15-epi-LXA4. In contrast, S-nitrosylation by PIO + ASA augments the production of both 15-epi-LXA4 and 6-keto-PGF1α. However, when COX2 is both acetylated and S-nitrosylated, it is inactivated. We suggest potential adverse interactions among statins, thiazolidinediones, and high-dose ASA.

KW - 15-Epi-lipoxin A

KW - Aspirin

KW - Atorvastatin

KW - Cycloxygenase

KW - Inflammation

KW - Pioglitazone

KW - Prostaglandins

KW - S-Nitrosylation

UR - http://www.scopus.com/inward/record.url?scp=33846528967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846528967&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2006.10.003

DO - 10.1016/j.prostaglandins.2006.10.003

M3 - Article

VL - 83

SP - 89

EP - 98

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

IS - 1-2

ER -